公开(公告)号：EP1785418A4

公开(公告)日：2009-11-11

申请号：EP05768611

申请日：2005-08-08

申请人： DAIICHI SEIYAKU CO

发明人： KANAYA NAOAKI ,  ISHIYAMA TAKASHI ,  MUTO RYO ,  WATANABE TOSHIYUKI ,  OCHIAI YUICHI

IPC分类号： C07D401/14 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61P7/02 ,  A61P9/10 ,  C07D403/14 ,  C07D413/14

CPC分类号： C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14

公开(公告)号：EP1621537A4

公开(公告)日：2008-12-31

申请号：EP04728462

申请日：2004-04-20

申请人： DAIICHI SEIYAKU CO

发明人： OKAYAMA TORU ,  UOTO KOUICHI ,  ISHIYAMA TAKASHI ,  KANAYA NAOAKI ,  KIMURA YOUICHI ,  ISHIHARA HIROAKI ,  WATANABE TOSHIYUKI ,  FUJII KUNIHIKO

IPC分类号： C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/499 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/553 ,  A61P7/02 ,  A61P9/10 ,  C07D401/06 ,  C07D413/06 ,  C07D413/14

CPC分类号： C07D401/14 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/499 ,  A61K31/501 ,  A61K31/5377 ,  A61K31/553

摘要： A compound represented by the general formula (I), a salt of the compound, or a solvate of either; a medicine containing any of these; an agent for the prevention of and/or treatments for ischemic diseases which contains any of these; and a platelet aggregation inhibitor containing any of these. The compound is useful as a potent platelet aggregation inhibitor which inhibits neither COX-1 nor COX-2.

公开(公告)号：EP1698626A4

公开(公告)日：2007-11-14

申请号：EP04807937

申请日：2004-12-27

申请人： DAIICHI SEIYAKU CO

发明人： KANAYA NAOAKI ,  ISHIYAMA TAKASHI ,  MUTO RYO ,  OCHIAI YUICHI ,  WATANABE TOSHIYUKI ,  SHIMA NORIKO

IPC分类号： C07D401/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61P7/02 ,  A61P9/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

CPC分类号： C07D401/14 ,  C07D401/04 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

摘要： A platelet aggregation inhibitor not inhibiting COX-1 and COX-2, comprised of a compound of the general formula: (I) (wherein each of Ar1 and Ar2 independently represents a 5- or 6-membered aromatic heterocycle optionally having one to three substituents, or phenyl optionally having one to three substituents; R1 is a lower acyl, carboxyl, a lower alkoxycarbonyl, a lower alkyl optionally having one or two substituents, carbamoyl optionally having one or two substituents, oxamoyl optionally having one or two substituents, amino optionally having one or two substituents, a 4- to 7-membered alicyclic heterocycle optionally having one or two substituents, phenyl optionally having one to three substituents, or a 5- or 6-membered aromatic heterocycle optionally having one to three substituents; and R2 is hydrogen, a halogeno, etc.).

摘要翻译： 一种不抑制COX-1和COX-2的血小板聚集抑制剂，其由通式（I）的化合物组成（其中Ar 1和Ar 2各自独立地表示任选具有1至3个取代基的5或6元芳族杂环 或任选具有一至三个取代基的苯基; R 1为低级酰基，羧基，低级烷氧基羰基，任选具有一个或两个取代基的低级烷基，任选具有一个或两个取代基的氨基甲酰基，任选具有一个或两个取代基的氧杂酰基， 具有一个或两个取代基，任选具有一个或两个取代基的4至7元脂环族杂环，任选具有1至3个取代基的苯基或任选具有1至3个取代基的5或6元芳香族杂环;并且R 2是 氢，卤代等）。

公开(公告)号：EP1346982A4

公开(公告)日：2005-08-10

申请号：EP01272548

申请日：2001-12-28

申请人： DAIICHI SEIYAKU CO

发明人： NAKAYAMA ATSUSHI ,  MACHINAGA NOBUO ,  YONEDA YOSHIYUKI ,  SUGIMOTO YUICHI ,  CHIBA JUN ,  WATANABE TOSHIYUKI ,  IIMURA SHIN

IPC分类号： A61P1/04 ,  A61P3/10 ,  A61P11/06 ,  A61P17/06 ,  A61P19/02 ,  A61P27/16 ,  A61P29/00 ,  A61P35/04 ,  A61P37/06 ,  C07C275/42 ,  C07D209/42 ,  C07D263/58 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04 ,  C07D491/04 ,  C07D491/056 ,  A61K31/423

CPC分类号： C07D263/58 ,  C07C275/42 ,  C07D209/42 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D471/04 ,  C07D491/04

摘要： Compounds represented by the general formula (I) or salts thereof, and medicines containing the same: (I) [wherein W is WA-A1-WB- (wherein WA is optionally substituted aryl or the like; A?1 is -NR1¿-, a single bond, -C(O)-, or the like; and WB is optionally substituted arylene or the like); R is a single bond, -NH-, -OCH¿2?-, alkenylene, or the like; X is -C(O)-, -CH2-, or the like; and M is, e.g., a group represented by the general formula (iii): (iii) (wherein R?11, R12, and R13¿ are each independently hydrogen, hydroxyl, amino, halogeno, or the like; R14 is hydrogen or lower alkyl; Y is -CH¿2?-O- or the like; Z is optionally substituted arylene or the like; A?2¿ is a single bond or the like; and R10is hydroxyl or lower alkoxy)]. The compounds or the salts selectively inhibit the binding of cell adhesion molecules to VLA-4 and exhibit high oral absorbability, thus being useful as preventive and/or therapeutic drugs for inflammatory diseases, autoimmune diseases, cancerous metastasis, bronchial asthma, nasal occlusion, diabetes, and so on.